Frontage Laboratories Inc. is a full-service early-stage contract research organization (CRO) with locations in the US and China. Last week the Exton, PA-headquartered company announced its acquisition of Concord Biosciences.
Previously under the name Ricerca Biosciences LLC, Concord Biosciences is a preclinical CRO located on a 20-acre campus near Cleveland, OH. The company conducts drug safety, metabolism, bioanalytical, residue and environmental fate studies.
Dr. Song Li, founder and CEO of Frontage Laboratories, said the acquisition is a “significant step” toward reaching the company’s goal of building a global CRO with integrated services.
“The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization,” he said in a press release. “Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry."
Frontage Laboratories has not responded to a request for comment.